NCT03357627 - A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2018

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions

Lymphoma, Non-HodgkinLymphoma, Large B-cell, DiffuseLymphoma, Follicular

Interventions

DRUG

TAK-659

TAK-659 tablets.

DRUG

Venetoclax

Venetoclax tablets.

Trial Locations (15)

10029

Icahn School of Medicine at Mount Sinai, New York

30322

Emory University, Atlanta

35249

University of Alabama at Birmingham, Birmingham

40065

Norton Cancer Institute - Shelbyville, Shelbyville

55131

Universitatsmedizin der Johannes Gutenberg Universitat, Mainz

60201

NorthShore Medical Group - Evanston, Evanston

60426

Ingalls Memorial Hospital, Harvey

60590

Universitatsklinikum Frankfurt, Frankfurt am Main

69120

Universitatsklinikum Heidelberg, Heidelberg

75246

Baylor Scott & White Research Institute, Dallas

81377

Universitatklinikum der Ludwig-Maximilians-Universitat Munchen, München

89081

Universitatsklinikum Ulm, Ulm

02215

Dana Farber Cancer Institute, Boston

H1T 2M4

Hopital Maisonneuve-Rosemont, Montreal

H3T 1E2

Jewish General Hospital, Montreal